InceptionR’s CRISPR Therapeutics CRSP Stock Holding History

InceptionR’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,577	Closed	-$313K	–	696
2026 Q1	$313K	Buy	+6,577	New	+$347K	0.08%	464

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

InceptionR's CRSP Position: Q2 2026 in Review

InceptionR sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 6,577 shares — an estimated $313K sold.

InceptionR first reported a position in CRSP in Q1 2026 and held it in 1 quarter. The position peaked at $313K in Q1 2026. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

InceptionR reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
InceptionR sold 6,577 CRISPR Therapeutics shares in Q2 2026, an estimated $313K.
InceptionR first reported a position in CRISPR Therapeutics in Q1 2026 and held it in 1 quarter.
InceptionR's CRISPR Therapeutics position peaked at $313K in Q1 2026.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on InceptionR's 13F filing for Q2 2026, filed 11 Aug 2026.